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Abstract

Author Manuscript

The synthesis and in vitro evaluation of four mesoporphyrin IX-peptide conjugates designed to
target EGFR, over-expressed in colorectal and other cancers, are reported. Two peptides with
known affinity for EGFR, LARLLT (1) and GYHWYGYTPQNVI (2), were conjugated to
mesoporphyrin IX (MPIX, 3) via one or both the propionic side chains, directly (4, 5) or with a
triethylene glycol spacer (7, 8). The conjugates were characterized using NMR, MS, CD, SPR,
UV-vis and fluorescence spectroscopies. Energy minimization and molecular dynamics suggest
different conformations for the conjugates. SPR studies show that conjugate 4, bearing two
LARLLT with no PEG spacers, has the greatest affinity for binding to EGFR, followed by
conjugate 7 with two PEG and two LARLLT sequences. Molecular modeling and docking studies
suggest that both conjugates 4 and 7 can bind to monomer and dimer EGFR in open and closed
conformations. The cytotoxicity and cellular targeting ability of the conjugates were investigated
in human HEp2 cells over-expressing EGFR. All conjugates showed low dark- and phototoxicities. The cellular uptake was highest for conjugates 4 and 8 and lowest for 7 bearing two
LARLLT linked via PEG groups, likely due to decreased hydrophobicity. Among the conjugates
investigated 4 is the most efficient EGFR-targeting agent, and therefore the most promising for the
detection of cancers that over-express EGFR.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers diagnosed in both men and
women, and the third leading cause of cancer-related deaths, expected to cause
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approximately 50,000 deaths in 2015 in the USA [1]. Since CRC develops overtime in the
body, screening methodologies have been developed to detect early stage cancers, with the
most cure potential. The detection and removal of polyps and early stage cancer has reduced
the incidence of CRC, and has led to the improvement in patient mortality observed in the
past 20 years. Two screening methods, chromoendoscopy and confocal laser
endomicroscopy (CLE), are particularly suited for the detection of small adenomas (< 5
mm) and flat lesions [2, 3]. These techniques use untargeted contrast dyes, such as
methylene blue, fluorescein, acriflavine, and cresyl violet that label both neoplastic and
normal mucosal tissue. Targeted agents with fluorescence emissions in the red and near-IR
regions could enhance specific delivery to CRC cells with reduced scattering, therefore
further improving early detection of small adenomas and further decreasing cancer mortality.
One very important target in CRC and several other tumors, such as breast, ovarian and
prostate cancers, is the human epidermal growth factor receptor (EGFR), known to be
abundantly expressed in both early and advanced CRC [4, 5]. EGFR is a transmembrane
glycoprotein with extracellular and intracellular domains, involved in the regulation of
signaling pathways that control cell proliferation, differentiation and angiogenesis [6].
Several targeting molecules based on monoclonal antibodies [6, 7], affibody proteins [8, 9],
peptides [10], peptomimetics [11, 12] and non-peptidic tyrosine kinase inhibitors [13, 14]
have been developed for specific targeting of EGFR. Among these, the use of small peptides
as ligands is a particularly attractive approach, because of their easy synthesis and
conjugation, and their low immunogenicity. Two peptide ligands, LARLLT and
YHWYGYTPQNVI, designed and investigated by Li et al. [15] and Song et al. [16],
respectively, have demonstrated high EGFR-targeting ability both in vitro and in vivo. We
have recently reported the synthesis of phthalocyanine (Pc) conjugates to one of these
peptides, linked to the Pc via a short five-atom or a PEG group [10]. Our studies revealed
that Pc conjugates to LARLLT (1) via a PEG spacer, showed enhanced water solubility and
targeting ability, accumulating in EGFR over-expressing cells up to 17 times more than
unconjugated Pc. However, some Pc conjugates showed very low solubility, in particular
those containing the peptide GYHWYGYTPQNVI (2). Herein we investigate conjugates of
peptides 1 and 2 to mesoporphyrin IX (MPIX, 3), bearing one or two peptide residues linked
via a short three-atom or a PEG linker. MPIX is a derivative of protoporphyrin IX (PPIX)
bearing ethyl rather than vinyl groups at the 3,8-positions, and two propionic acids available
for conjugation that allow easy introduction of one or two peptide residues. Several
conjugates of porphyrins and derivatives to various peptide sequences have been reported
[17]. For example, conjugates of PPIX to GnRH-targeting peptides [18] and integrintargeting peptides, including cycloRGDfk [19], cycloERGDF [20], ATWLPPR [20] and
PQRRSARLSA [20] were prepared and shown to have enhanced targeting ability relative to
unconjugated PPIX. We have also investigated the use of a low molecular weight
polyethylene glycol (PEG) linker between the PPIX and the peptide sequence to enhance the
conjugates’ aqueous solubility, reduce intramolecular interactions and favor cellular uptake
[20]. In this work, four amphiphilic MPIX conjugates bearing two LARLLT (1) or one
GYHWYGYTPQNVI (2) sequences linked directly to the propionic acid group(s) or via low
molecular weight PEG spacers, were synthesized and their structures investigated by NMR,
MALDI-MS, UV-vis, CD and molecular modeling. Their EGFR-binding ability was studied
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using SPR, and in cell culture using human HEp2 cells. Based on these experimental studies,
a model for binding of conjugates to EGFR protein has been proposed.

RESULTS AND DISCUSSION
Synthesis

Author Manuscript

The MPIX conjugates 4, 5, 7 and 8 were prepared as shown in Scheme 1. The peptide
sequences LARLLT (1) and GYHWYGYTPQNVI (2) were synthesized on Fmoc-Pal-PEGPS resin using solid phase peptide synthesis [10, 21]. An aminium coupling agent, TBTU, a
triazole as electron-poor coupling additive, HOBt, and DIEA as base were used in the solid
phase synthesis of 1 and 2 [10, 21–23]. A polar aprotic solvent, DMF, enabled the swelling
of the Fmoc-PAL-PEG-PS resin, expanding the active sites and facilitated amino acid
coupling to the resin. The C-terminus of the first amino acid was first coupled to the resin
followed by the removal of the Fmoc protecting group. The next amino acid was applied to
the resin and the procedure repeated until the desired peptide was obtained. In the final step,
the protecting group was removed and the peptide was cleaved from the resin and purified
by reverse phase HPLC. Peptides 1 and 2 were isolated in 48% and 32%, respectively (Table
1).
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MPIX conjugate 4 bearing two LARLLT sequences was prepared by conjugating 1 (2 equiv)
to 3 in solution phase, using TBTU, HOBt and DIEA in DMF (Scheme 1). The desired
conjugate 4 was isolated in 83% yield after purification by solid phase extraction (SPE).
Under similar conditions, MPIX conjugate 5 bearing only one GYHWYGYTPQNVI
sequence was also synthesized, as indicated by MALDI-MS, however in low yield (<5%),
probably due to higher steric hindrance. Therefore, alternative reaction conditions were
investigated for the coupling of 2 to 3, using the organophosphorus DEPBT and the
phosphonium salt PyAOP as the coupling agents. DEPBT is normally used to reduce
racemization of amino acids, such as tyrosine, serine, threonine, and the imidazole group of
histidine [24, 25]. Since peptide 2 contains tyrosine, threonine and histidine residues,
DEPBT might be an effective coupling agent for this peptide. On the other hand, PyAOP has
been used in challenging coupling reactions, producing cleaner products [26, 27]. Using
these reagents, conjugate 5 was isolated in 51% and 20% yields, respectively, following
purification by SPE (Table 1).
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The conjugation of MPIX to low molecular weight PEG groups bearing a protected
carboxylic acid was accomplished using TBTU, HOBt and DIEA in DMF (Scheme 1). After
purification by column chromatography, the tert-butyl ester protecting group was cleaved
using TFA, giving MPIX-diPEG 6 in 88% yield. Peptides 1 and 2 were conjugated to
porphyrin 6 under similar conditions to those described above, producing conjugates 7 and 8
in 16% and 39% yields, respectively (Scheme 1). The retention time, coupling conditions,
and yields obtained for peptides 1 and 2 and for porphyrins 4–8 are listed in Table 1.
The structure of the porphyrin conjugates was confirmed by NMR, MALDI-MS and UV-vis
spectrophotometry. The spectroscopic properties were investigated in DMF solution and the
results obtained are shown in Fig. 1 and summarized in Table 2. The absorption and
emission spectra of the porphyrin conjugates were similar to that of MPIX 3, with slight redJ Porphyr Phthalocyanines. Author manuscript; available in PMC 2016 October 11.

Fontenot et al.

Page 4

Author Manuscript

shifts observed for the Soret bands for 4, 7 and 8. The conjugates’ fluorescence quantum
yields were in the range 0.086–0.13, similar to that reported for porphyrin 3 (ΦF = 0.102)
[28]. The quantum yields were slightly larger for the porphyrins conjugated to peptide 2
rather than 1, and were also enhanced for the conjugates bearing PEG spacers, maybe as a
result of their higher solubility in DMF.
Circular Dichroism (CD)

Author Manuscript

The solution conformation of the peptides 1 and 2 and porphyrin conjugates 4 and 7 (bearing
two LARLLT sequences linked directly or via PEG spacers to the propionic acid groups of
MPIX) were investigated by CD in a membrane-mimicking environment (0.5 mM PBS
buffer with 10% TFE). The CD spectra obtained for 1 and 2 up to 1 mM and for 4 and 7 at
15 and 37.5 μM concentrations are shown in Fig. 2, and the molar ellipticity (θ) values are
listed in Table 3. For peptide 1, a sharp negative band at ~198 nm and a broad, less intense,
negative band at around 225 nm were observed at the highest concentrations (Fig. 2a),
suggesting an unordered structure, as expected for a small peptide containing six amino acid
residues. On the other hand, peptide 2 showed a negative band at ~198 nm at concentrations
<125 μM. This is indicative of a random coil conformation, and two negative bands at 208
and 217 nm at higher concentrations, suggests a mixture of α-helix and β-sheet
conformations (Fig. 2b).

Author Manuscript

We have previously observed that peptide sequences conjugated to meso-tetraarylporphyrins
via low molecular weight PEG spacers tend to assume extended conformations, in which the
peptide retains its original conformation [29–31]. To evaluate the influence of peptide
conjugation to the propionic acid groups of MPIX (3), either directly or via two PEG
spacers, the CD spectra of conjugates 4 and 7 were obtained at 15 and 37.5 μM
concentrations. Porphyrin conjugate 4 exhibited a positive peak at ~200 nm, a negative peak
at ~217 nm and a small shoulder at ~222 nm, suggesting a mixture of α-helical and β-sheet
conformations in solution (Fig. 2c). On the other hand, the CD spectrum obtained for
porphyrin conjugate 7 at 15 μM suggests an α-helix conformation with a positive band at
~193 nm and two negative bands at ~205 and 227 nm. However, at 37.5 μM conjugate 7
appears to adopt a 310-helix conformation [32] with a positive band at 195 nm and two
negative bands at 205 and 228 nm (Fig. 2d). A web-based program, K2D2, was used to
assess the percentage of secondary structures, α-helix and β-sheet, present in the
conformations of conjugates 4 and 7 [33]. Analysis of the results indicated that 4 has 2% (15
μM) — 25% (37.5 μM) α-helix and 48% (15 μM) — 25% (37.5 μM) β-sheet whereas 7 has
3% (15 μM) — 14% (37.5 μM) α-helix and 47% (15 μM) — 27% (37.5 μM) β-sheet [34].
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Surface Plasmon Resonance (SPR)
SPR is an optical technique used to evaluate the interaction between an immobilized ligand
and an analyte [35, 36]. The EGFR was immobilized onto the gold surface of a chip where
the binding and specificity of peptides 1 and 2, and porphyrins 3, 4, 5, 6 and 7 were
evaluated. The results obtained are shown in Fig. 3. The relative binding affinity of peptides
and conjugates were determined by the maximum response units (RU) reached during
association immediately following the injection during the association phase. All conjugates
showed higher binding affinity to EGFR than the peptides alone (Fig. 3a) and porphyrin
J Porphyr Phthalocyanines. Author manuscript; available in PMC 2016 October 11.
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conjugate 4 showed the greatest binding affinity to EGFR of all compounds tested (Fig. 3b).
This may in part be due to the hydrophobic nature of the porphyrin macrocycle, which
favors binding to the surface of the EGFR protein, as we previously observed with
phthalocyanine conjugates [10]. The determined binding affinity (kRU) order is 4 ≫ 7 > 6 ~
3 > 5 > 2 > 1. Of the two peptides, 2 showed higher binding affinity than 1, probably
because 2 binds to the EGF binding pocket [15] while 1 preferentially binds to a pocket
away from the EGF binding site in EGFR [16]. Nevertheless, the conjugates bearing two
LARLLT sequences, 4 and 7, showed enhanced binding compared with the unconjugated
porphyrins 3 and 6, and to conjugate 5 bearing the GYHWYGYTPQNVI sequence. The
remarkable strong binding observed for conjugate 4 might in part be due to the +2 charge on
the two arginine residues [37, 38]. Dissociation of the bound molecules was observed around
400 s on the sensogram. Conjugates 4, 5 and 7 exhibited slower dissociation rates (Fig. 3)
from 400 to 500 s whereas, other conjugates showed relatively rapid dissociation from the
EGFR protein.
Molecular modeling studies
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Computational studies were performed to gain further insight on the conformations of the
porphyrin conjugates, using energy minimization and molecular dynamics methods in
vacuum, and in the presence of water molecules. Results of these studies are shown in Fig.
4. In vacuum, conjugate 4 with two LARLLT sequences (Fig. 4a) showed one of the
peptides folded over the porphyrin ring and the other peptide in an extended conformation to
minimize steric interactions between the two peptides, while maximizing stabilizing
intramolecular interactions with the porphyrin ring. We have previously observed that
porphyrin-peptide conjugates bearing short linkers tend to assume folded conformations due
to hydrogen bonding and hydrophobic intramolecular interactions, which reduce the
conformational entropy compared with the linear conformations [37]. On the other hand, in
the presence of water, both peptide chains were extended away from the porphyrin ring
suggesting that the interaction of solvent with the peptide chains stabilizes the peptide
structure (Fig. 4b). The energy-minimized structure of porphyrin 6, bearing two PEG chains,
in vacuum, indicated that the PEG groups are completely folded and interacted with the
porphyrin ring, stabilizing the PEG chain structure via hydrophobic interactions (Fig. 4c).
Such folded or curled conformations of PEG groups attached to porphyrin derivatives, in the
gas phase or water MD simulations have been previously observed [39, 40]. In the presence
of water, we observed slight folding of the PEG group positioned away from the porphyrin
ring (Fig. 4d). In conjugate 7, bearing two PEG and two LARLLT peptide chains, similar
results were observed. In vacuum, the PEG groups were folded onto the porphyrin ring
while the peptide extended away from the ring (Fig. 4e). In the presence of water, although
the PEG groups were slightly folded towards the porphyrin ring, the overall PEG and
peptide chains were extended away from porphyrin ring (Fig. 4f). The energy-minimized
conformation of conjugate 5, bearing a single GYHWYGYTPQNVI sequence showed an
extended conformation that allows the aromatic amino acids (histidine and tyrosine) to
extended away from the peptide backbone (not shown). Conjugate 8 bearing one
GYHWYGYTPQNVI sequence linked via a PEG group also adopted an extended
conformation (not shown). In agreement with these results, we have previously reported that
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a PEG spacer tends to minimize folding of the peptide over the porphyrin ring, favoring an
extended conformation of the conjugate [29].
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Since conjugates 4 and 7 exhibited the strongest binding to EGFR by SPR, their mode of
interaction with EGFR was modeled using Autodock [41, 42]. For conjugate protein
complexes, the models of conjugates generated in solvent molecules were used since these
are the most relevant in the presence of the receptor. Furthermore, the models generated in
water showed extended structures rather than folded structures, as observed in vacuum (Fig.
4). EGFR exists in both open and closed conformations, and in cancers over-expressing
EGFR the majority of the protein exists in the open conformation, which is active for signal
transduction processes [43–45]. Based on our previous studies [10], peptide 1 binds to
domain I of the extracellular domain and a site on EGFR that is not affected by
conformational changes. Therefore, we modeled the interaction of conjugates 4 and 7 with
EGFR in both open and closed conformations, as shown in Figs 5a and 5b. The low energy
docked structure of peptide 1 to EGFR domain 1 was found to be −5.9 kcal/ mol. Since
peptide 1 binds to both open and closed conformations, conjugates 4 and 7 can also bind to
both conformations of EGFR. Furthermore, we investigated the hypothesis that conjugates 4
and 7 might bind to two, rather than one, EGFR molecule simultaneously, therefore
increasing their binding affinity as observed by SPR. Therefore, the binding of conjugates 4
and 7 to EGFR dimers in open and closed conformations were modeled. Our model suggests
that the porphyrin and peptide length in both conjugates 4 and 7 are suitable to bind to two
EGFR molecules (Fig. 5). EGFR does not form dimers to generate signaling in closed
conformation. Binding of EGF to EGFR or over-expression of receptors on the cell surface
induces conformational change from closed to open conformation [43, 45]. However, our
SPR data suggests that peptide 1 as well as its conjugates 4 and 7 bind to EGFR domain 1 in
the absence of ligand EGF, indicating that the conjugates also bind to EGFR in closed
conformation. Such models have been proposed in the literature for binding of bi-specific
affibody ligands that target EGFR and HER2 dimers [46], as well as HER2 dimers in open
and closed conformations [47]. Hence, our SPR and modeling studies suggest that
conjugates 4 and 7 can bind to monomer EGFR, as well as dimer EGFR, in open or closed
conformations.
Cellular studies

Author Manuscript

The cytotoxicity and time-dependent uptake of conjugates 4, 5, 7 and 8, and of porphyrin 3
for comparison purposes, were investigated in human carcinoma HEp2 cells, and the results
obtained are shown in Fig. 6 and Table 4. The dark cytotoxicity was evaluated at
concentrations up to 400 μM and the phototoxicity (light dose ~1.5 J/cm2) at concentrations
up to 200 μM, using the Cell Titer Blue (CTB) assay. All compounds were found to be nontoxic in the dark (IC50 > 400 μM) and only conjugates 4 and 5 showed moderate
phototoxicity, with calculated IC50 values of 50 and 150 μM, respectively (Table 4). These
results show that the absence of a PEG spacer between the peptide and the porphyrin
enhances the phototoxicity of the conjugate. This might be due to the different
conformations assumed by the conjugates in the presence and absence of PEG groups,
which influences their binding to EGFR and biodistribution.
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The time-dependent cellular uptake of porphyrin 3 and conjugates 4, 5, 7, and 8 was
investigated at 10 μM concentrations over a period of 24 h. Conjugates 4, 5 and 8
accumulated within cells to a much larger extent than MPIX 3 at all time points investigated;
however, conjugate 7 accumulated significantly less despite its positive charge, probably as a
result of its higher hydrophilicity induced by the two PEG spacers between the porphyrin
and the two LARLLT peptides. On the other hand, conjugate 8 bearing two PEG groups and
one GYHWYGYTPQNVI sequence steadily accumulated overtime, and after 24 h showed
similar uptake as conjugate 4, about 8-fold more than MPIX 3. Conjugate 4 accumulated the
most at times < 4 h. These results indicate that the nature of both the peptide and linker
affect EGFR targeting and cellular uptake. We have previously observed that in multimeric
porphyrin-peptide conjugates, the most amphiphilic molecules tend to show enhanced
cellular uptake [31].
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Another factor known to influence cellular uptake in peptide conjugates is their polar surface
area (PSA), which takes into account the solvent-accessible surface areas of the molecules
[48, 49]. The PSA values calculated for peptides 1 and 2, porphyrins 3 and 6 and conjugates
4, 5, 7, and 8 are given in Table 5. In general, low PSA values favor cell permeability and
bioavailability. The PSA for peptide 2 is nearly double that for 1, indicating that the latter is
significantly more cell permeable, as expected for the smaller sequence containing one
cationic residue. Porphyrin 3 has the smallest PSA value, followed by 6. Among the
conjugates, those bearing the larger GYHWYGYTPQNVI sequence show larger PSA than
the corresponding conjugates bearing two LARLLT sequences, and conjugate 4 has the
lowest PSA value of the series, which might contribute to its high uptake. On the other hand,
conjugate 8 bearing the largest PSA and molecular weight was also observed to have high
cellular uptake, maybe due to its favorable amphiphilicity.
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EXPERIMENTAL
Synthesis
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General—All reagents and solvents were purchased from commercial suppliers and used
directly without further purification. O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
tetrafluoroborate (TBTU), hydroxybenzotriazole (HOBt), 7-azabenzotriazol-1yloxy)tripyrrolidnophosphonium hexafluorophosphate (PyAOP), 3(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), N-hydroxysuccinimide
(NHS), 1-ethyl-3-(3-diimethylaminopropyl) carbodiimide (EDC), 1,8-diazabicycloundec-7ene (DBU), piperidine, N,N-diisopropylethylamine (DIEA), methanol (MeOH),
dichloromethane (DCM), 2,2,2-trifluoroethanol (TFE), ethylacetate, acetone, acetonitrile,
liquefied phenol, anhydrous ethyl ether, triisopropylsilane (Tips), sodium acetate, and
sodium chloride were purchased from Sigma Aldrich. N,N-dimethylformamide (DMF)
peptide sequencing grade, dimethyl sulfoxide (DMSO) cell culture grade, Cremophor EL,
trifluoroacetic acid (TFA), malonic acid, oxalic acid, phosphoric acid, and formic acid were
purchased from Fisher Scientific. Phosphate buffer solution (PBS) was purchased from
VWR International. The peptide sequences were synthesized on an automated peptides
synthesizer from Applied Biosystems Pioneer. Analytical thin-layer chromatography (TLC)
was carried out using plastic backed TLC plates 254 (precoated, 200 μm) from Sorbent
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Technologies. Silica gel 60 (230 × 400 mesh, Sorbent Technologies) was used for column
chromatography. Prevail C18 reverse phase extract clean was purchased from Grace Davison
Discovery Sciences and was used for SPE. NMR spectra were recorded on Liquid AV-400
Bruker spectrometer (400 MHz for 1H, 100 MHz for 13C). The chemical shifts are reported
in δ ppm using the following deuterated solvents as internal references: CD3COCD3 2.04
ppm (1H), 29.92 ppm (13C); DMF-d7 8.03 ppm (1H), 163.15 ppm (13C). MALDI-TOF mass
spectra were recorded on a Bruker UltrafleXtreme (MALDI-TOF/TOF) instrument using 4chloro-α-cyanocinnamic acid (CCA) as the matrix. HPLC purifications were carried out on
a Waters system including a 2545 quaternary gradient module pump, 2489 UV-visible
detector, and a fraction collector III. Analytical HPLC was carried out using a XBridge C18
300 Å, 5 μm, 4.6 × 250 mm (Waters, USA) or an Atlantis C18 300 Å, 5 μm, 4.6 × 250 mm
(Waters, USA). Semipreparative HPLC was carried out on XBridge C18 300 Å, 5 μm, 10 ×
250 mm (Waters, USA) column. The HPLC solvents contained 0.1% TFA in Millipore water
(A) and HPLC grade acetonitrile (B). All tissue culture medium and reagents such as fetal
bovine serum (FBS) and penicillin streptomycin (PS) were purchased from Invitrogen.
Human carcinoma HEp2 cells were purchased from ATCC. The HEp2 cells were cultured
and maintained in 50:50 ATCC formulated Dulbecco’s Modified Eagle’s Medium (DMEM)
and advanced MEM (AMEM). A BMG FluoStar Optima micro-plate reader was used for the
cell culture assays. Surface Plasmon Resonance was performed using Biacore X100 from
GE Health Sciences. Pure recombinant protein EGFR was obtained from Leinco
Technologies. The EGF ligand was obtained from Abcam, Inc. 4-(2-Hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid (EDTA), and 100
mM glycine at pH 1.5 and 2.5 were purchased from GE Health Science.
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Peptides—Peptide sequences LARLLT (1) and GYHWYGYTPQNVI (2) were prepared
on an automated peptides synthesizer in a 0.2 mmol scale using standard Fmoc strategy, as
we have previously reported [10]. A cleavage cocktail of TFA (88%), Millipore water (5%),
liquefied phenol (5%) and Tips (2%) was added to the resin for 3–5 h, then released into
cold (−80 °C) anhydrous ethyl ether (5 × 40 mL), and centrifuged. The supernatant was
decanted and the residue washed with cold anhydrous ethyl ether. The solid was dissolved in
a mixture of Millipore water (A) and acetonitrile (B), freeze-dried and lyophilized. The
solvent system for purification of the peptides consisted of Millipore water and HPLC grade
acetonitrile with 0.1% TFA. Peptide 1 was obtained as a white solid (145 mg, 48%). HPLC
(90% A for 1 min, 90% A to 30% A over 34 min, 30% A to 90% A over 1 min at a flow rate
of 1 mL/min) and tR = 18.02 min. The spectroscopic data agrees with that previously
reported [15]. Peptide 2 was obtained as a white solid (98 mg, 32%). This peptide was
synthesized as per the procedure in literature [16], with an addition of glycine to reduce
steric interference from tyrosine. HPLC (90% A for 1 min, 90% A to 10% A over 34 min,
10% A to 90% A over 1 min at a flow rate of 5 mL/min) and tR = 31.22 min. 1H NMR (dDMSO, 400 MHz): δ, ppm 10.7 (1H, s, ε NH His), 9.18–9.14 (3H, d, J = 18.13 Hz, ι NH
Trp, ζ CH His), 8.58–8.49 (2H, m, NH Gly, NH His), 8.32–8.26 (3H, m, NH Tyr), 8.15–8.10
(6H, m, NH Trp, NH Thr, NH Gln, NH Asn, NH Val, NH Ile), 7.56–7.52 (1H, d, ε CH Trp),
7.41 (1H, s, δ CH His), 7.29 (2H, d, J = 8.18 Hz, ζ CH Trp), 7.08–6.97 (12H, m, δ CH Tyr,
κ CH Trp, η CH Trp, NH2 Asn, NH2 Gln), 6.75 (2H, s, NH2 Ile), 6.68–6.58 (6H, m, ε CH
Tyr), 4.69 (1H, s, α CH Thr), 4.60–4.55 (5H, m, ζ OH Tyr, α CH Trp, α CH His), 4.52–4.48
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(1H, m, α CH Pro), 4.45–4.41 (2H, m, α CH2 Gly), 4.39–4.32 (3H, m, α CH Ile, α CH Val,
α CH Gln), 4.20–4.12 (4H, m, α CH Tyr, α CH Asn), 4.06 (2H, t, J = 8.18 Hz, α CH2 Gly),
3.88–3.83 (2H, m, δ CH2 Pro), 3.08–2.81 (9H, m, β CH2 Tyr, β CH2 His, β CH Thr), 2.72–
2.63 (5H, m, β CH Val, β CH2 Asn, β CH2 Trp), 2.13 (3H, t, J = 7.16 Hz, β CH2 Pro, β CH
Ile), 2.06–1.98 (2H, m, γ CH2 Pro), 1.92–1.81 (4H, m, β CH2 Gln, γ CH2 Gln), 1.23 (2H, s,
NH2 Gly), 1.10 (6H, s, γ CH2 Ile, γ CH3 Thr), 0.89–0.78 (12H, m, ε CH3 Ile, δ CH3 Ile, γ
CH3 Val). MS (MALDI): m/z 1619.80 [M + Na]+, calcd. for C77H101N19O19 1619.74.
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MPIX conjugate 4: To a solution of MPIX 3 (19 mg, 0.030 mmol) in DMF (1 mL) was
added DIEA (17 mg, 0.13 mmol) under N2 at 37 °C, and the final solution stirred at room
temperature for 2 h. TBTU (10 mg, 0.031 mmol), HOBt (5 mg, 0.037 mmol), DMF (2 mL),
and DIEA (17 mg, 0.13 mmol) were added and the mixture allowed to stir for 30 min under
N2 at 37 °C. Peptide 1 (41 mg, 0.060 mmol) was dissolved in DMF (500 μL) and DIEA (17
mg, 0.128 mmol) and added to the reaction flask. The mixture was stirred for 5 days and
dried under N2. A solution consisting of MeOH/acetone/acetonitrile (0.5/6/3.5, 4 mL) was
used for SPE. The SPE was conditioned with methanol (10 mL, 5 times), Millipore water
(10 mL, 5 times) and MeOH/acetone/ acetonitrile (3 × 10 mL). The crude product was
sonicated in MeOH/acetone/acetonitrile (0.5/6/3.5, 5 mL) and loaded onto the SPE cartridge.
The cartridge was eluted until the solvent was clear and TFA was added to the solvent
system to elute the compound that was stuck on the column. The title conjugate 4 was
obtained (30.3 mg) in 83% yield. HPLC (90% A for 1 min, 90% A to 50% A over 5 min,
50% A to 30% A over 55 min, 30% A to 90% A over 1 min at a flow rate of 0.6 mL/min)
and tR = 35.01 min. UV-vis (DMF): λmax, nm (log ε) 407 (5.19), 497 (4.06), 530 (4.00), 577
(3.93), 615 (3.63). 1H NMR (d-DMF, 400 MHz): δ, ppm 10.43 (1H, s, MPIX), 10.33 (3H, s,
MPIX), 8.51 (2H, s, η NH Arg), 8.41 (2H, s, NH Thr), 8.30 (2H, s, ε NH Arg), 8.00–7.95
(2H, m, NH Ala), 7.93–7.86 (4H, m, NH Leu), 7.58–7.50 (8H, m, NH Leu, NH2 Thr, NH
Arg), 7.17 (4H, d, J = 8.42 Hz, ζ NH2 Arg), 4.57–4.45 (4H, m, α CH Ala, α CH Thr), 4.42–
4.32 (8H, m, α CH Leu, α CH Arg), 4.29–4.20 (12H, m, β CH Thr, OH Thr, MPIX), 3.78–
3.70 (12H, m, MPIX), 3.42–3.34 (8H, m, δ CH2 Arg, MPIX), 1.95–1.85 (10H, m, MPIX, β
CH2 Arg), 1.78–1.68 (22H, m, β CH2 Leu, γ CH2 Arg, γ CH Leu), 1.35–1.23 (6H, m, β
CH3 Ala), 1.25–1.13 (6H, m, γ CH3 Thr), 0.93–0.78 (36H, m, ε CH3 Leu). MS (MALDITOF): m/z 1900.40 [M + 1]+, calcd. for C96H154N24O16 1900.41.
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MPIX conjugate 5: To a solution of MPIX 3 (8.32 mg, 0.030 mmol) in DMF (1 mL) was
added DIEA (5.6 mg, 0.043 mmol) under inert conditions, and the mixture was stirred at
37 °C for 2 h. DEPBT (8.2 mg, 0.027 mmol), HOBt (12.3 mg, 0.032 mmol), DMF (2 mL),
and DIEA (5.6 mg, 0.043 mmol) were added and the final mixture allowed to stir for 30 min
under N2 at 37 °C. Peptide 2 (41.5 mg, 0.026 mmol) dissolved in DMF (500 μL) and DIEA
(5.6 mg, 0.043 mmol) was added and the mixture allowed to stir at 37 °C for 5 days. The
SPE was conditioned with methanol (5 × 10 mL), Millipore water (5 × 10 mL) and
MeOH/DCM (3 × 10 mL). Unreacted MPIX 3 was soluble in MeOH/DCM and eluted off
the SPE while 5 remained on the SPE. The cartridge was eluted until the solvent was clear
and TFA added to the solvent system to elute conjugate 5, obtained (8 mg) in 51% yield.
HPLC gradient (90% A for 1 min, 90% A to 50% A over 5 min, 50% A to 10% A over 52
min, 10% A to 90% A over 3 min at a flow rate of 0.7 mL/min) and tR = 36.20 min. UV-vis
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(DMF): λmax, nm (log ε) 397 (5.19), 497 (4.06), 530 (4.00), 566 (3.93), 620 (3.63). 1H
NMR (d-DMF, 400 MHz): δ, ppm 10.80 (1H, s, ε NH His), 10.45 (1H, s, MPIX), 10.34 (3H,
s, MPIX), 9.07 (3H, d, J = 11.70 Hz, ι NH Trp, ζ CH His), 8.52–8.25 (6H, m, NH Gly, NH
Tyr, NH His), 7.77–7.65 (4H, m, NH Trp, NH Thr, NH Gln, NH Asn), 7.46 (1H, s, NH Val),
7.34 (1H, m, NH Ile), 7.30–7.18 (3H, m, ε CH Trp, δ CH His, η CH Trp), 7.15–6.82 (14H,
m, ζ CH Trp, δ CH Tyr, κ CH Trp, NH2 Asn, NH2 Gln, NH Gly), 7.05–6.60 (8H, m, NH2
Ile, ε CH Tyr), 4.78–4.65 (4H, m, MPIX), 4.58–4.43 (5H, m, ζ OH Tyr, α CH Trp, α CH
His), 4.35–4.24 (15H, m, α CH Pro, α CH Thr, α CH2 Gly, α CH Ile, MPIX), 3.79–3.66
(19H, m, α CH Asn, α CH Tyr, δ CH2 Pro, α CH Gln, MPIX), 3.46–3.27 (5H, m, MPIX, α
CH Val), 3.16–3.09 (2H, m, β CH Thr, OH Thr), 2.44–2.33 (6H, m, β CH2 Tyr), 2.27–2.19
(3H, m, β CH2 His, β CH Val), 2.15–1.95 (2H, m, β CH2 Trp), 1.89–1.75 (12H, m, β CH2
Asn, β CH2 Pro, β CH Ile, MPIX, γ CH2 Pro) 1.30–1.20 (12H, m, β CH2 Gln, γ CH2 Gln, ε
CH3 Ile, γ CH3 Thr, γ CH2 Ile), 0.93–0.75 (9H, m, γCH3 Val, δ CH3 Ile). MS (MALDI):
m/z 2146.26 [M + 1]+, calcd. for C111H137N23O22 2146.24.
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MPIX-diPEG 6: To a solution of MPIX 3 (20.26 mg, 0.032 mmol) in DMF (1 mL) was
added DIEA (14 mg, 0.106 mmol) under inert conditions, and the mixture was stirred at
37 °C for 2 h. TBTU (21.4 mg, 0.066 mmol), HOBt (10.7 mg, 0.079 mmol), DMF (2 mL),
and DIEA (14 mg, 0.106 mmol) were added and the final mixture stirred for 30 min under
N2 at 37 °C. tert-Butyl-12-amino-4,7,10-trioxadodecanoate (17.6 mg, 0.063 mmol)
dissolved in DMF (500 μL) and DIEA (14 mg, 0.106 mmol) was added and the mixture
allowed to stir at 37 °C for 5 days. The reaction mixture was diluted with water and ethyl
acetate (3/7), transferred to a separatory funnel and gently swirled. The organic layer was
concentrated under reduced pressure. The crude product was purified by column
chromatograph using methanol/dichloromethane (5/95) for elution. 1H NMR (d-DMF, 400
MHz): δ, ppm 10.40 (1H, s, MPIX), 10.29 (3H, s, MPIX), 8.10–8.02 (2H, m, NH PEG),
4.48–4.41 (4H, m, CH2 MPIX), 4.22–4.18 (4H, m, CH2 MPIX), 3.80 (4H, s, OCH2), 3.75–
3.70 (14H, m, γ CH2), 3.59 (2H, d, J = 3.23 Hz, γ CH2 PEG), 3.46 (4H, t, J = 6.14 Hz, CH2
MPIX), 3.25–3.17 (12H, m, CH3 MPIX), 3.06–3.01 (8H, t, J = 5.50 Hz, β CH2 PEG, δ CH2
PEG), 2.93–2.87 (2H, m, α CH2 PEG), 2.38–2.30 (4H, m, ε CH2 PEG), 1.95–1.88 (6H, m,
CH3 MPIX), 1.40–1.34 (18H, m, tBu). The protected porphyrin was dissolved in TFA (2
mL) and stirred at 0 °C for 4 h. The TFA was evaporated under N2 and purified using HPLC.
Conjugate 6 was obtained in 88% yield; HPLC gradient (90% A for 1 min, 90% A to 40% A
over 10 min, 40% A to 20% A over 30 min, 20% A to 10% A over 3 min, 10% A to 90% A
over 2 min at a flow rate of 0.6 mL/min) and tR = 19.43 min. UV-vis (DMF): λmax, nm (log
ε) 398 (5.35), 497 (4.18), 530 (4.18), 566 (4.00), 616 (3.70). 1H NMR (d-DMF, 500 MHz):
δ, ppm 10.29 (2H, s, MPIX), 10.23 (2H, s, MPIX), 8.08–8.01 (2H, m, PEG), 4.44–4.38 (4H,
m, CH2 MPIX), 4.25–4.18 (4H, m, CH2 MPIX), 3.80 (4H, s, OCH2), 3.72–3.65 (14H, m, γ
CH2 PEG), 3.60–3.55 (2H, m, γ CH2 PEG), 3.34–3.25 (4H, m, CH2 MPIX), 3.20–3.15
(12H, m, CH3 MPIX), 3.10–3.02 (4H, m, β CH2 PEG), 2.95–2.86 (8H, m, δ CH2 PEG, α
CH2 PEG), 2.46–2.40 (4H, m, ε CH2 PEG), 1.92–1.80 (6H, m, CH3 MPIX). MS (MALDI):
m/z 974.50 [M]+ calcd. for C52H72N6O12 974.53.
MPIX conjugate 7: To a solution of MPIX-diPEG 6 (13.94 mg, 0.014 mmol) in DMF (1
mL) was added DIEA (6.20 mg, 0.047 mmol) under inert conditions, and the mixture was
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stirred at 37 °C for 2 h. TBTU (9.65 mg, 0.030 mmol), HOBt (4.84 mg, 0.036 mmol), DMF
(2 mL), and DIEA (6.20 mg, 0.047 mmol) were added and the final mixture allowed to stir
for 30 min under N2 at 37 °C. Peptide 1 (19.6 mg, 0.029 mmol) dissolved in DMF (500 μL)
and DIEA (8.3 mg, 0.064 mmol) was added and the final mixture was allowed to stir for 5
days. The crude product was dissolved in MeOH/acetone/ acetonitrile (5/60/35) and loaded
into a C18 SPE. The SPE was conditioned with methanol (5 × 10 mL), Millipore water (5 ×
10 mL) and MeOH/acetone/acetonitrile (3 × 10 mL). When the washes were clear TFA was
added to the solvent system to elute the compound, affording conjugate 7 (5.4 mg) in 16%
yield. HPLC gradient (90% A for 1 min, 90% A to 50% A over 4 min, 50% A to 10% A
over 38 min, 10% A to 90% A over 2 min at a flow rate of 0.6 mL/min) and tR = 19.86 min.
UV-vis (DMF): λmax, nm (log ε) 408 (5.19), 497 (4.08), 530 (4.00), 573 (3.90), 618
(3.60). 1H NMR (d-DMF, 400 MHz): δ, ppm 10.46 (1H, s, MPIX), 10.33 (3H, s, MPIX),
8.49–8.42 (6H, m, η NH Arg, NH Thr, ε NH Arg), 7.90 (6H, d, J = 5.83 Hz, NH Leu), 7.81
(2H, d, J = 6.72 Hz, NH Ala), 7.46 (4H, d, J = 8.52 Hz, NH2 Thr), 7.09 (4H, d, ζ NH2 Arg),
4.51–4.46 (8H, m, MPIX), 4.41–4.36 (4H, m, α CH Ala, α CH Thr), 4.30–4.22 (26H, m, α
CH Leu, β CH Thr, OH Thr, MPIX), 3.79–3.71 (22H, m, PEG, MPIX), 3.65–3.55 (12H, m,
PEG), 2.48–2.44 (4H, m, δ CH2 Arg), 1.90 (16H, t, J = 7.27 Hz, β CH2 Arg, β CH2 Leu),
1.78–1.66 (21H, m, γ CH2 Arg, γ CH2 Leu, MPIX), 1.41–1.34 (6H, m, β CH3 Ala), 1.22–
1.15 (7H, m, γ CH3 Thr), 0.89–0.76 (36H, m, δ CH3 Leu). MS (MALDI): m/z 2306.48 [M
+ 1]+, calcd. for C114H188N26O24 2306.43.
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MPIX Conjugate 8: To a solution of MPIX-diPEG 6 (7.29 mg, 0.008 mmol) in DMF (1
mL) was added DIEA (3.25 mg, 0.025 mmol) and the mixture was stirred at 37 °C for 2 h.
DEPBT (4.79 mg, 0.016 mmol), HOBt (6.84 mg, 0.018 mmol), DMF (2 mL), and DIEA
(3.25 mg, 0.025 mmol) were added and the final mixture allowed to stir for 30 min under N2
at 37 °C. Peptide 2 (28.72 mg, 0.15 mmol) dissolved in DMF (500 μL) and DIEA (4.16 mg,
0.032 mmol) was added and the final mixture was allowed to stir for 5 days. The sample was
dissolved in acetone, sonicated, and centrifuged several times to remove the unreacted
compound 6. The title bioconjugate 8 was obtained (7.3 mg) in 39% yield. HPLC gradient
(90% A for 1 min, 90% A to 50% A over 4 min, 50% A to 10% A over 38 min, 10% A to
90% A over 2 min at a flow rate of 0.6 mL/min) and tR = 25.862 min. UV-vis (DMF): λmax,
nm (log ε) 408 (5.24), 497 (4.15), 531 (4.08), 574 (4.00), 620 (3.60). 1H NMR (d-DMF, 400
MHz): δ, ppm 10.30 (1H, s, CH, MPIX), 10.23 (3H, s, CH, MPIX), 9.14 (3H, s, ι NH Trp, ε
NH His, ζ CH His), 8.23–8.08 (4H, m, NH Gly, NH Tyr), 7.94–7.78 (4H, m, NH His, NH
Trp, NH Thr, NH Gln), 7.68 (6H, m, NH Asn, NH Val, NH Ile, NH PEG, δ CH His), 7.51–
7.42 (2H, m, γ CH His, ε CH Trp), 7.33–7.20 (4H, m, ζ CH Trp, η CH Trp, κ CH Trp),
7.05–6.92 (12H, m, δ CH Tyr, NH2 Asn, NH2 Gln, NH2 Ile), 6.61 (6H, d, J = 6.05 Hz, ε CH
Tyr), 4.69 (2H, s, α CH Thr, α CH Trp), 4.57 (3H, q, J = 4.03 Hz, OH Tyr), 4.44–4.34 (7H,
m, α CH His, α CH Gln, α CH Pro, MPIX), 4.18–4.05 (16H, m, MPIX, α CH Ile, α CH
Val, α CH2 Gly, α CH Asn, α CH Tyr, δ CH2 Pro), 3.68–3.54 (26H, m, MPIX, PEG), 3.36–
3.25 (16H, m, PEG), 3.20–3.03 (14H, m, β CH2 Tyr, β CH2 His, β CH2 Trp, PEG), 2.72–
2.65 (3H, m, β CH Val, β CH2 Asn), 2.15–1.98 (5H, m, β CH Ile, β CH2 Pro, γ CH2 Pro),
1.87–1.65 (17H, m, β CH2 Gln, γ CH2 Gln, MPIX, γ CH2 Ile, PEG), 1.13–1.05 (6H, m, ε
CH3 Ile, γ CH3 Thr), 0.87–0.75 (9H, m, δ CH3 Ile, γ CH3 Val). MS (MALDI): m/z 2551.23
[M + 1]+, calcd. for C129H171N25O30 2552.27.
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Circular dichroism (CD) studies were performed using a Jasco J-815 spectrometer or on an
AVIV 620S circular dichroism spectrometer. The CD measurements were carried out using 1
mm path length quartz cell. Peptide solutions at various concentrations were prepared in
PBS/TFE (9/1) with a pH of 7.4. All spectra correspond to an average of three runs and were
corrected using the baseline obtained for peptide free solutions.
Spectroscopic properties
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Photophysical studies were performed in peptide-sequencing grade DMF solutions. All
absorption spectra were measured on a UV-vis Perkin Elmer Lambda 35 spectrophotometer.
All experiments were carried out within 3 h of solution preparation at room temperature
(23–25 °C) using a 10 mm path length spectrophotometric cell. Emission spectra were
recorded on a Fluorolog®-HORIBA JOBINVYON (Model LFI-3751). The fluorescence
quantum yields (Φf) were determined using a secondary standard method using MPIX 3 (Φf
= 0.102) as the reference [28].
SPR studies
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Surface Plasmon Resonance was performed using Biacore X100 (GE Health Sciences) at
25 °C. EGFR was immobilized on a CM5 chip using a standard amine coupling protocol.
The carboxyl groups on the sensor chip were activated using 0.2 M EDC and 0.05 M NHS
solution in Millipore water (flow rate 5 μL/min). Running buffer consisted of 0.01 M
HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% Tween at pH 7.5 (adjusted using 4 M NaOH).
Regeneration buffer for the ligand were 50% acid cocktail (0.15 M malonic acid, 0.15 M
oxalic acid, 0.15 phosphoric acid, 0.15 formic acid, adjusted to pH 5 with 4 M NaOH).
Regeneration buffer for porphyrin conjugates was 100 mM glycine at pH 2.5 and 100 mM
glycine at pH 1.5. For immobilization EGFR was dissolved in NaOAc at pH 4.5 (adjusted
using 10% HCl) and injected onto the chips surface at 10 μL/min until 12 000 response units
(RU) was obtained. The remaining unreacted activated groups were blocked with 1 M
ethanolamine at pH 8.5 (adjusted with 10% HCl). Peptides 1 and 2 were dissolved in DMSO
and diluted in running buffer to obtain the desired concentration. Porphyrin conjugates 4, 5
and 7 were dissolved in 10% Cremophor EL in DMSO and diluted in the running buffer to
obtain the desired concentration, with maximum DMSO concentration of 1% and
Cremophor EL concentration of 0.1%. All solutions were filtered using 0.45 μm filters and
the concentration of the peptides was 100 μM.
Computational studies
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Three dimensional structures of conjugates 4, 5, 6, 7 and 8 were generated using InsightII
(BIOVIA, Sandiego CA) software. These structures were energy minimized by using 100
steps of steepest descent method to remove any short contacts and further minimized for
4000 steps of conjugate gradient method in vacuum. Minimized structures were subjected to
20 ps molecular dynamics simulations at 300 K. Resulting structures were analyzed using
time vs. energy graph. From the MD simulations structures were selected at the end of 20 ps
and further minimized. These minimized structures were used as representative 3D
structures of conjugates. For computational studies in solvent, starting conjugate structures
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were soaked with a 5 Å layer of water molecules and after equilibration, minimization and
dynamics were performed as described above. Final structures were represented using
PyMol software (Schrodinger Inc. LLC, Portland OR).
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Docking of peptides and conjugates to EGFR was performed using Autodock 4 software
[41, 42] using monomer of EGFR structure. A three dimensional structure of conjugate 4
was generated using InsightII (BIOVIA, San Diego, CA). Three dimensional structures of
EGFR in the open (3njp) [41] and closed (1nql) [42] conformations were obtained from the
protein data bank. The 3D structure of conjugate 4 was generated as described above using
molecular modeling and energy minimization. Using the previously published docking
results [10], the structure of conjugates 4 and 7 were placed on the binding site of one EGFR
molecule in open conformation, via one of the peptide chains. Another EGFR molecule was
placed on the other peptide chain of 4 or 7. The two EGFR molecules were rotated and
translated so there was no steric clash between the two, however the EGRF binding site for
peptide was maintained [10]. A similar procedure was used for generating the binding model
of 4 and 7 to EGFR in a closed conformation. The models were energy minimized to remove
any possible steric hindrance. Final models were represented using PyMol software
(Schrodinger Inc. LLC, Portland OR).
Cell studies

Author Manuscript

The HEp2 cells (ATCC) were maintained in a 75 cm2 flask (Chemglass) with the medium
(DMEM:Advanced, 1:1) containing 10% FBS and 1% antibiotic (Life Technologies). The
compound solutions were prepared by dissolving the compound in 100% DMSO at a
concentration of 32 mM (stock solution), and a 2 mL of 400 μM compound solution was
prepared by adding 25 μL of the 32 mM compound stock solution into 1975 μL growing
medium.
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Dark cytotoxicity—To investigate the compound dark toxicity, HEp2 cells were placed in
a 96-well plate (15,000 cells/well). The cell will be treated with the compound concentration
of 200, 100, 50, 25, 12.5, and 0 μM for 20–24 h incubation at 37 °C when each well cell get
100% confluence. To end the treatment, the compound was removed by washing cells with
1X PBS and replaced with the growing media containing 20% CellTiter Blue (Promega).
This cell viability assay uses the indicator dye resazurin which is reduced to highly
fluorescent resorufin in viable cells, while non-viable cells lose metabolic capacity and are
not able to reduce resazurin nor to generate a fluorescent signal. This is a popular, simple,
fast, sensitive and accurate method for determination of cell viability that has been
demonstrated to correlate well with other methods for measuring cell proliferation and
cytotoxicity. The cells were incubated for an additional 4 h at 37 °C, and measured
fluorescently at 570/615 nm using a FluoStar Optima micro-plate reader.
Phototoxicity—The concentration range of 100, 50, 25, 12.5, 6.25, 3.125, and 0 μM was
used for the phototoxicity experiments. HEp2 cells were placed in 96 well plates as
described above, and treated with compound for 24 h at 37 °C. After this treatment the
loading media was removed. The cells were washed with 1 X PBS buffer, and then refilled
with fresh media. The cells were exposed to a 600 W halogen lamp light source filtered with
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a water filter (transmits radiation 250–950 nm) and a beam turning mirror (Newport) with
200 nm to 30 μm spectral range, for 20 min. The total light dose was approximately 1.5 J/
cm2. After exposed to light, the cells were returned to the incubator for 24 h. After 24 h
incubation, the medium was removed and replaced with media containing 20% Cell Titer
Blue. The cells were incubated for an additional 4 h. The viable cells is measured
fluorescently at 570/615 nm using a FluoStar Optima micro-plate reader.

Author Manuscript

Time-dependent cellular uptake—The HEp2 cells were plated in a 96-well plate as
described above. The cells were treated by adding 100 μL/well of 10 μM working solution at
different time periods of 0, 1, 2, 4, 8, and 24 h whenever the cell getting 90–100%
confluence monolayer. The 10 μM compound working concentration was made by diluting
400 μM stock solution with growing medium. At the end of the treatments, the cells were
washed with 1X PBS, and solubilized by adding 100 μL 0.25% Triton X-100 in 1X PBS per
well. A compound standard curve was made by diluting 400 μM compound solution with
0.25% Triton X-100 in 1X PBS to 10, 5, 2.5, 1.25, 0.625, 0.3125, and 0 μM. A cell standard
curve was prepared using 10,000, 20,000, 40,000, 60,000, 80,000, and 100,000 cells/well.
The cells were quantified by CyQuant Cell Proliferation Assay (Life Technologies). The
compound and cell number were determined using a FluoStar Optima micro-plate reader
(BMG LRBTEH), with wavelengths 355/615 nm for compounds and 485/520 nm for cells,
respectively. Cellular uptake was expressed in terms of nM compound per cell.

CONCLUSION

Author Manuscript

Two EGFR-targeting peptides with the sequences LARLLT and GYHWYGYTPQNVI were
synthesized, characterized, and conjugated to the propionic side chains of mesoporphyrin
IX, with or without a triethylene glycol spacer. The conjugations were performed in solution
phase at room temperature in DMF, using TBTU/HOBt as the coupling agents for the
shorter peptide, and DEPBT/HOBt for the longer peptide. Four conjugates, containing two
LARLLT sequences (4 and 7) or one GYHWYGYTPQNVI sequence (5 and 8) were
isolated in 16–83% yields.
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The structures of the peptides and their conjugates were investigated by NMR, MALDI-MS,
CD, UV-vis and fluorescence spectroscopies. SPR, molecular dynamics and docking
investigations were used to evaluate their conformations and binding to EGFR. These studies
revealed that the conjugates 4 and 7 containing two LARLLT residues have the highest
affinity for binding to EGFR, in both open and closed conformations. Furthermore,
modeling studies suggested that these two conjugates can also bind to EGFR dimers. The
observed enhanced binding of the porphyrin-LARLLT conjugates may be a result of their
positive charge and amphiphilic character.
All conjugates were non-toxic in the dark (IC50 > 400 μM), and only conjugate 4 showed
moderate phototoxicity (IC50 = 50 μM at 1.5 J/cm2 light dose) toward human HEp2 cells.
Conjugates 4 and 8 were the most efficiently taken up by cells, while 7 was the least, due to
its lower hydrophobicity. Our results show that amphiphilic mesoporphyrin IX conjugates
bearing the LARLLT peptide are very promising for selective EGFR targeting, and hence for
the diagnosis of EGFR-over-expressing cancers, such as CRC.
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Fig. 1.

Absorption (a, c) and fluorescence (b, d) spectra of porphyrins 3 (black), 4 (red), 5 (purple),
6 (pink), 7 (green), and 8 (blue) in DMF at room temperature
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Fig. 2.
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CD spectra of peptides 1 (a), 2 (b) and porphyrin conjugates 4 (c) and 7 (d) in 0.5 mM PBS
buffer with 10% TFE, at different concentrations
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Fig. 3.
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SPR sensorgram of peptides binding to EGFR extracellular domain. (a) 1 (turquoise), 2
(orange) and porphyrins 3 (black), 4 (red), 5 (purple), 6 (pink) and 7 (green) at 100 μM. (b)
SPR sensorgrams of 1 to 7 without conjugate 4 (red) is shown for the sake of clarity. Based
on the maximum RU reached during association, affinity order is 4 ≫ 7 > 6 ~ 3 > 5 > 2 > 1
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Fig. 4.
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Energy minimized conformations in a vacuum and in the presence of solvent (layer of water
molecules). (a) conjugate 4 in vacuum, (b) conjugate 4 in water, (c) porphyrin 6 in vacuum,
(d) porphyrin 6 in water, (e) conjugate 7 in vacuum, and (f) conjugate 7 in water
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Fig. 5.

Author Manuscript

Proposed model of conjugates 4 (a, c) and 7 (b, d) binding with two molecules of EGFR in
open conformation (a, b) and in closed conformation (c, d). Crystal structure of EGFR
(3NJP) was used for modeling the dimers of EGFR
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Fig. 6.
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Time-dependent uptake of porphyrins 3 (black), 4 (red), 5 (purple), 7 (green), 8 (blue) at 10
μM by HEp2 cells
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Scheme 1.

Synthetic route to porphyrin-peptide conjugates from MPIX 3
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Coupling conditions used in the synthesis of compounds 1, 2, 4–8, HPLC retention times (see experimental
section for conditions) and isolated yields
Compound

Rt, min

1

18.02

TBTU/HOBT/DMF/DIEA

48%

2

31.22

TBTU/HOBT/DMF/DIEA

32%

4

35.01

TBTU/HOBT/DMF/DIEA/37 °C

83%

5

36.20

PyAOP/HOBT/DMF/DIEA

20%

DEPBT/HOBT/DMF/DIEA/37 °C

51%

6

19.43

TBTU/HOBT/DMF/DIEA/37 °C

88%

7

19.86

TBTU/HOBT/DMF/DIEA/37 °C

16%

8

25.86

DEPBT/HOBT/DMF/DIEA/37 °C

39%

Conditions

Yield, %
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Spectroscopic data for porphyrins 4, 5, 6, 7 and 8 in DMF at room temperature

a

Porphyrin

Absorption (λmax, nm)

Emission (λmax, nm)

Stokes shift, nm

Φfa

4

407, 497, 530, 577, 615

618, 645, 665, 684

220

0.089

5

397, 497, 530, 566, 620

620, 646, 670, 690

223

0.124

6

398, 497, 530, 566, 616

618, 651, 665, 684

220

0.086

7

408, 497, 530, 573, 618

620, 655, 670, 686

212

0.124

8

408, 497, 531, 574, 620

621, 655, 670, 686

213

0.132

Calculated using porphyrin 3 as standard (0.102) [28].
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Molar ellipticity values for peptides and select conjugates in 0.5 mM PBS with 10% TFE at pH 7.4
Concentration, μM

Molar ellipticity θ (deg.cm2.dmol−1)

1

50

−59 355 (197 nm)

2

50

−24 097 (198 nm)

4

37.5

−5519 (217 nm)

15

−4921 (213 nm) and −4223 (224 nm)

37.5

−13 129 (205 nm) and −4860 (227 nm)

15

−3821 (205 nm) and −2854 (227 nm)

Porphyrin

7
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Cytotoxicity (CTB assay, light dose ~1.5 J/cm2) for porphyrin conjugates in HEp2 cells
Porphyrin

Dark toxicity IC50, μM

Phototoxicity IC50, μM

3

> 400

4

> 400

50

5

> 400

150

7

> 400

> 200

8

> 400

> 200

> 200
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Polar surface area (PSA) of peptides, porphyrins and their conjugates
Porphyrin

PSA, Å2

1

326

2

613

3

123

4

648

5

702

6

237

7

762

8

816
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